Can-Fite Biopharma Ltd ADR (CANF)

$3.17 -0.16 (-4.80%)
Market Cap 4.50M
Revenue (ttm) 670,000.00
Net Income (ttm) -7.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,176.12%
Debt to Equity Ratio 0.00
Volume 49,900
Avg Vol 858,296
Day's Range N/A - N/A
Shares Out 1.31M
Stochastic %K 2%
Beta 1.01
Analysts Sell
Price Target $70.00

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 924 1114
Fax: 972 3 924 9378
Address:
26 Ben Gurion Street, Ramat Gan, Israel
Peaceouty
Peaceouty Mar. 20 at 10:33 PM
$CANF These people are running a snake oil scam for over 20 years. Unbelievable!
0 · Reply
GeeJoon
GeeJoon Mar. 20 at 4:36 PM
$CANF the valuation is insane, 7m only with 2 pivotal P3, tutes are scared of CANF management and shitty price action
1 · Reply
GeeJoon
GeeJoon Mar. 20 at 4:31 PM
$CANF veterinary market looks more promising...upfront and royalties on sales upon regulatory approval for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch.
0 · Reply
Farhas80
Farhas80 Mar. 20 at 1:57 PM
$CANF This stupid stock keep going down because of stupid management. I thought I bought good price around 4:50. No news no rebound.
0 · Reply
PhishTourFunds
PhishTourFunds Mar. 20 at 12:34 PM
$CANF 200SMA is about $10.50 now Massive volume and price pump to $12 earlier this month looks like an exit event similar to mid November ‘25.
0 · Reply
GeeJoon
GeeJoon Mar. 18 at 4:16 PM
$CANF will they attend Bio Europe and disclose the data of pancreatic cancer p2a
2 · Reply
Farhas80
Farhas80 Mar. 18 at 3:14 PM
$CANF just bought 5k for rebound.
0 · Reply
Farhas80
Farhas80 Mar. 18 at 3:02 PM
$CANF Stock is 10 years low and management is quite.
0 · Reply
Farhas80
Farhas80 Mar. 17 at 7:46 PM
$CANF we touching almost 10 years low and company still not releasing something good.
0 · Reply
GeeJoon
GeeJoon Mar. 17 at 2:19 PM
$CANF u know why no tutes investing this shit, all CANF claimed were only patent, safety, patent, safety
0 · Reply
Latest News on CANF
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

Tue, 17 Mar 2026 07:47:00 -0400 - 4 days ago

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

2026-03-04T16:50:16.000Z - 17 days ago

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Wed, 04 Mar 2026 10:07:28 -0500 - 17 days ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

2026-03-04T15:07:28.000Z - 17 days ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

2026-03-04T12:34:33.000Z - 17 days ago

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Wed, 04 Mar 2026 07:00:00 -0500 - 17 days ago

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

2026-02-17T12:36:34.000Z - 4 weeks ago

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

2026-02-09T12:30:05.000Z - 5 weeks ago

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

2026-02-05T12:33:49.000Z - 6 weeks ago

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

2026-01-20T12:37:35.000Z - 2 months ago

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

2025-12-23T22:55:20.000Z - 3 months ago

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

2025-12-23T22:25:23.000Z - 3 months ago

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Tue, 23 Dec 2025 16:46:00 -0500 - 3 months ago

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

2025-12-17T13:30:15.000Z - 3 months ago

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

2025-12-16T15:29:50.000Z - 3 months ago

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

Can-Fite Provides Update on Clinical and Financial Status

Tue, 16 Dec 2025 09:19:00 -0500 - 3 months ago

Can-Fite Provides Update on Clinical and Financial Status

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

2025-11-24T12:30:24.000Z - 4 months ago

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

2025-11-20T12:42:31.000Z - 4 months ago

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Thu, 20 Nov 2025 07:00:00 -0500 - 4 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News

2025-11-18T20:00:37.000Z - 4 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News

Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival

2025-11-18T12:30:20.000Z - 4 months ago

Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival

CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News

2025-11-04T12:01:46.000Z - 4 months ago

CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News

CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News

2025-09-16T12:32:06.000Z - 6 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News

Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment

2025-09-15T12:40:09.000Z - 6 months ago

Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Thu, 28 Aug 2025 08:47:00 -0400 - 7 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Wed, 30 Jul 2025 07:04:00 -0400 - 8 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Can-Fite Announces Up To $15.0 Million Public Offering

Mon, 28 Jul 2025 12:24:00 -0400 - 8 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Mon, 28 Jul 2025 07:00:00 -0400 - 8 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Thu, 17 Apr 2025 08:55:00 -0400 - 1 year ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Mon, 14 Apr 2025 14:28:00 -0400 - 1 year ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Thu, 20 Mar 2025 09:45:00 -0400 - 1 year ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Wed, 19 Mar 2025 09:00:00 -0400 - 1 year ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Mon, 03 Mar 2025 06:00:00 -0500 - 1 year ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Mon, 10 Feb 2025 07:10:00 -0500 - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Wed, 05 Feb 2025 07:00:00 -0500 - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Mon, 30 Dec 2024 07:00:00 -0500 - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 22 Nov 2024 09:00:00 -0500 - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Mon, 11 Nov 2024 07:00:00 -0500 - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Mon, 04 Nov 2024 07:08:00 -0500 - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Fri, 18 Oct 2024 09:06:00 -0400 - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Wed, 09 Oct 2024 07:00:00 -0400 - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Mon, 16 Sep 2024 07:00:00 -0400 - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Thu, 29 Aug 2024 08:15:00 -0400 - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Can-Fite Provides Namodenoson Patent Update

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 29, 2024, 7:00 AM EDT - 1 year ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 27, 2024, 7:00 AM EDT - 1 year ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 23, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 13, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 10, 2024, 9:00 AM EDT - 2 years ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 9, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

May 6, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Feb 28, 2024, 7:00 AM EST - 2 years ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Jan 30, 2024, 7:00 AM EST - 2 years ago

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Jan 29, 2024, 7:00 AM EST - 2 years ago

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Peaceouty
Peaceouty Mar. 20 at 10:33 PM
$CANF These people are running a snake oil scam for over 20 years. Unbelievable!
0 · Reply
GeeJoon
GeeJoon Mar. 20 at 4:36 PM
$CANF the valuation is insane, 7m only with 2 pivotal P3, tutes are scared of CANF management and shitty price action
1 · Reply
GeeJoon
GeeJoon Mar. 20 at 4:31 PM
$CANF veterinary market looks more promising...upfront and royalties on sales upon regulatory approval for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch.
0 · Reply
Farhas80
Farhas80 Mar. 20 at 1:57 PM
$CANF This stupid stock keep going down because of stupid management. I thought I bought good price around 4:50. No news no rebound.
0 · Reply
PhishTourFunds
PhishTourFunds Mar. 20 at 12:34 PM
$CANF 200SMA is about $10.50 now Massive volume and price pump to $12 earlier this month looks like an exit event similar to mid November ‘25.
0 · Reply
GeeJoon
GeeJoon Mar. 18 at 4:16 PM
$CANF will they attend Bio Europe and disclose the data of pancreatic cancer p2a
2 · Reply
Farhas80
Farhas80 Mar. 18 at 3:14 PM
$CANF just bought 5k for rebound.
0 · Reply
Farhas80
Farhas80 Mar. 18 at 3:02 PM
$CANF Stock is 10 years low and management is quite.
0 · Reply
Farhas80
Farhas80 Mar. 17 at 7:46 PM
$CANF we touching almost 10 years low and company still not releasing something good.
0 · Reply
GeeJoon
GeeJoon Mar. 17 at 2:19 PM
$CANF u know why no tutes investing this shit, all CANF claimed were only patent, safety, patent, safety
0 · Reply
DARKP00L
DARKP00L Mar. 17 at 11:50 AM
$CANF 07:49 on Mar. 17 2026 Can‑Fite BioPharma Secures Israeli Patent Allowance For A3AR Agonists, Covering Namodenoson In Obesity And Fat‑Loss Use #tradeideas
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 17 at 11:48 AM
$CANF - Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 17 at 11:47 AM
$CANF Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
0 · Reply
GeeJoon
GeeJoon Mar. 16 at 5:31 PM
$CANF many catalysts in 2026 but market seems not interested... - pancreatic cancer p2a result - MASH p2b result - psoriasis p3 interim result - HCC CPB7 p3 interim result
0 · Reply
GeeJoon
GeeJoon Mar. 16 at 2:40 PM
$CANF potential revenues from dogs are more than human lol
0 · Reply
Farhas80
Farhas80 Mar. 16 at 2:13 PM
$CANF stupid management need to release some news.
0 · Reply
GeeJoon
GeeJoon Mar. 14 at 12:27 PM
$CANF
0 · Reply
GeeJoon
GeeJoon Mar. 14 at 12:18 PM
$CANF
0 · Reply
Peaceouty
Peaceouty Mar. 13 at 10:05 PM
$CANF Closest catalyst is the failure of the phase 3 psoriasis trial (again). Very unlikely to get approved. Only chance it has is its safety. Yet I don’t trust management. They don’t respond to my emails. :(
2 · Reply
GeeJoon
GeeJoon Mar. 13 at 8:38 PM
$CANF the main issue is no tutes are buying this shit, they are all scared of the management's financial operation
0 · Reply
GeeJoon
GeeJoon Mar. 13 at 8:37 PM
$CANF 4m raised, 1/8 of them go to Pnina Fishman annual pay, do you think that witch worth it? found the company over 30 years but still no product in market, but a little revenue from compassionate use?
0 · Reply
GeeJoon
GeeJoon Mar. 13 at 8:08 PM
$CANF CANF is a nightmare for retailers, management don't give a fuck about stock price, they heavily dilute, execute warrants in vastly discounted price several times, those cash are mainly for Pnina's overvalued salary and countless cosmetic products
0 · Reply